UNSPSC 51162725: Guaiacol propionate

This classification denotes a topical anti-infective agent and expectorant with the molecular formula C10H12O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z7SCO70Q61. Most nations, for tariff and trade purposes, schedule guaiacol propionate under HS 29095000. As of Q4 2014, GUAIACOL PROPIONATE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)OC1CCCCC1OC.

UNSPSC 51162725 Guaiacol propionate is a Commodity code that nominally names a chemical compound, but state and local procurement activity under this code shows a mismatch between the code designation and actual buying patterns. The recent opportunities tagged to this code involve naloxone (an opioid antagonist), safe drug deactivation systems, and broad-based pharmaceutical and over-the-counter product procurement — none of which are guaiacol propionate. The work being solicited is pharmaceutical product supply and community health support, not the procurement of a single chemical intermediate. State and local governments use this code framing to acquire medical countermeasures, generic drugs, and OTC products through direct purchase and cooperative purchasing arrangements.

Recent activity spans Florida and Minnesota-led multi-state cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to its Community Health Building in Sanford, requiring electronic bid submission by July 26, 2023, and imposing E-Verify and drug-free workplace compliance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract execution targeted for July 1, 2026 through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. The MMCAP procurement weights price competitiveness at 75 percent and requires cGMP and DSCSA compliance along with commercial general liability insurance of $5 million per occurrence.